Applications of 3-(Dimethylcarbamoyl)Phenylboronic Acid in Industrial Manufacturing

We manufacture 3-(Dimethylcarbamoyl)Phenylboronic Acid to serve advanced performance requirements in targeted chemical industry segments. This material is implemented in specific downstream processes where boronic acid functionalities enable reliable transformations, selective coupling, and integration into specialty molecules. Below are the principal applications where this intermediate achieves real-world adoption at an industrial scale.

1. Active Pharmaceutical Ingredient (API) Synthesis: Suzuki Coupling Intermediates

In pharmaceutical manufacturing, this boronic acid derivative acts as a key cross-coupling partner in Suzuki-Miyaura reactions for synthesizing biaryl and heteroaryl units within API molecules. Production teams introduce it at the intermediate building block stage to construct complex drug frameworks, especially where carbamoyl boronates are required for selectivity or process safety. Ingredient loading depends on stoichiometry with aryl halide coupling partners and scales with campaign size, following API plant batch protocols.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
• US Pharmacopeia (USP) and European Pharmacopeia (Ph. Eur.) monographs, where applicable for starting materials
• FDA 21 CFR Part 210/211 for cGMP drug substance production
• ISO 9001:2015 Quality Management in fine chemical manufacturing

Typical usage ratio

• 0.95–1.10 molar equivalent per halogenated aromatic substrate
• Adjusted in pilot or scale-up phases to minimize unreacted excess while ensuring complete conversion, depending on catalyst system and reaction yield targets

Downstream process integration

• Charged directly into palladium-catalyzed Suzuki cross-coupling reactors after pre-dissolution step
• Isolated crude intermediates undergo purification (typically crystallization or chromatography) prior to downstream derivatization steps
• Effluent and byproducts from final coupling captured for QC analysis to verify suitability for further transformations

Final product types

• Targeted oncology small molecules (e.g., kinase inhibitors featuring biaryl frameworks)
• Antiviral and anti-inflammatory pharmaceutical actives
• Specialty drug intermediates for investigational new drugs (INDs) and generic molecule pipelines

2. Agrochemical Synthesis: Herbicide Intermediate Manufacturing

Chemical process operators in the agrochemical sector use this boronic acid to introduce aromatic carbamoyl groups during the synthesis of specific herbicide intermediates. It supports selective C-C coupling and ring functionalization, contributing to the construction of molecular structures in certain phenylcarbamate and biaryl herbicidal actives. Integration typically occurs at multi-step intermediate stages under controlled, closed-system operations in accordance with crop protection ingredient protocols.

Industry compliance standards

• FAO/WHO Technical Guidelines for pesticide formulation
• ISO 9001:2015 certified process management systems
• REACH (EC) 1907/2006 registration for EU chemical manufacturing
• OECD Principles of Good Laboratory Practice (GLP) for agrochemical R&D and pre-registration batches

Typical usage ratio

• 1.0–1.2 molar equivalents per synthetic step, depending on conversion efficiency and crop protection product registration batch requirements
• Adjusted in semi-batch versus continuous processes to maintain downstream product purity and yield

Downstream process integration

• Added after initial halogenated precursor arylation or derivatization, often following deprotection or ring-closure steps
• Processed under nitrogen atmosphere to minimize side-reactions and protect sensitive functionalities
• Purification performed via liquid-liquid extraction or preparative HPLC prior to final formulation

Final product types

• Phenylcarbamate-based herbicide actives
• Biphenyl derivatives for weed management in cereal crops
• Specialty pesticide intermediates requiring boronic acid precursors

3. OLED Material Development: Hole-Transport Layer Precursor

Research and development facilities that manufacture organic light emitting diode (OLED) components utilize this phenylboronic acid as an essential intermediate in crafting advanced hole-transport materials. Chemical engineers apply it in coupling reactions for producing carbamoyl-substituted biphenyl or triarylamine frameworks, which optimize charge mobility properties in display and lighting applications. The ratio varies with device architecture, targeting reproducible film formation and interface stability for end-device quality standards.

Industry compliance standards

• RoHS Directive 2011/65/EU on the use of hazardous substances in electrical and electronic equipment
• ISO 9001:2015 for OLED component material supply
• Internal quality control SOPs for trace metal and organic purity in optoelectronic intermediates
• IEC 62341 for OLED device reliability (downstream integration)

Typical usage ratio

• 0.90–1.05 equivalents per coupling operation, based on upstream aryl halide concentration and desired conversion rate
• Process engineers refine the charge to balance batch reproducibility and downstream molecular weight control

Downstream process integration

• Charged at pre-polymerization or pre-coupling step in specialty reactor vessels under inert gas
• Purified intermediates are converted further to functionalized triarylamine or arylamine derivatives before device fabrication
• Residues and QA samples analyzed for electronic grade purity before release

Final product types

• Hole-transport layer compounds for display and lighting OLEDs
• Functional intermediates for organic semiconductors
• Organic electronic materials for flexible panel production

4. Diagnostic Reagent Manufacturing: Boronate-Based Affinity Ligand Production

Specialty biochemical manufacturers employ this compound as a precursor in creating boronate affinity ligands used for protein and glycoprotein capture in chromatographic media. The boronic acid group allows selective binding and reversible release with cis-diol biomolecules, crucial for diagnostic columns and sensor calibration solutions. Raw material addition is carefully controlled to ensure ligand functionality and stability in aqueous and biological environments for end-user dependence.

Industry compliance standards

• ISO 13485:2016 for medical device and diagnostic reagent manufacturing
• FDA 21 CFR Part 820 for quality system regulation in diagnostics
• ISO 9001:2015 for specialty chemical component manufacturing
• CLSI Guideline EP25 for clinical assay development (where applicable)

Typical usage ratio

• 0.8–1.2 molar equivalents per resin matrix or polymer backbone, depending on immobilization efficiency and final column activity requirements
• Variation managed with in-process monitoring of ligand density and binding site availability

Downstream process integration

• Reacted during immobilization onto synthetic polymers, silica, or agarose beads via covalent attachment chemistry
• Purification steps include washing and elution with controlled buffers to remove unbound substrate and stabilize ligand orientation
• Final packed columns undergo leak testing, shelf-life stabilization, and binding capacity QA inspection

Final product types

• Boronate-functional affinity chromatography media
• Protein and glycoprotein capture columns for analytical and preparative work
• Diagnostic assay kits utilizing boronate-ligand separation modules